返回 
加入收藏
枸地氯雷他定与阿伐斯汀递减疗法治疗慢性荨麻疹的疗效比较
x
请在关注微信后，向客服人员索取文件
| 篇名： | 枸地氯雷他定与阿伐斯汀递减疗法治疗慢性荨麻疹的疗效比较 |
| TITLE： | |
| 摘要： | 目的：比较枸地氯雷他定与阿伐斯汀递减疗法治疗慢性荨麻疹的疗效和安全性。方法：132例慢性荨麻疹患者随机分为A组（62例）和B组（70例）。A组患者第1～2周口服枸地氯雷他定片8.8 mg，每日1次；第3～4周给予8.8 mg，每2日1次；第5～6周给予8.8 mg，每3日1次；第7～8周给予8.8 mg，每4日1次；第9～10周给予8.8 mg，每5日1次。B组患者第1～2周口服阿伐斯汀胶囊8 mg，每日3次；第3～4周给予8 mg，每日2次；第5～6周给予8 mg，每日1次；第7～8周给予8 mg，每2日1次；第9～10周给予8 mg，每3日1次。两组患者疗程均为10周。观察两组患者的临床疗效，治疗前后的血浆组胺水平和症状体征总积分，并随访两组患者停药4周后的复发情况及不良反应发生情况。结果：两组患者总有效率、不良反应发生率比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者血浆组胺水平和症状体征总积分均显著低于同组治疗前，差异均有统计学意义（P＜0.01），但两组比较差异无统计学意义（P＞0.05）。A组患者复发率显著低于B组，差异均有统计学意义（P＜0.05）。结论：枸地氯雷他定与阿伐斯汀递减疗法治疗慢性荨麻疹的疗效和安全性均相当，但枸地氯雷他定在降低复发率方面优于阿伐斯汀。 |
| ABSTRACT： | OBJECTIVE：To compare the efficacy and safety of desloratadine citrate disodium and acrivastine decremental therapy in the treatment of chronic urticaria. METHODS： 132 patients with chronic urticaria were randomly divided into group A （62 cases） and group B （70 cases）. Group A was orally given 8.8 mg Desloratadine citrate disodium tablet in 12 2 weeks， once a day； 8.8 mg in 3-4 weeks， once every 2 days； 8.8 mg in 5-6 weeks， once every 3 days； 8.8 mg in 7-8 weeks， once every 4 days； and 8.8 mg in 9-10 weeks， once every 5 days. Group B was orally given 8 mg Acrivastine capsule in 12 2 weeks， 3 times a day； 8 mg in 3-4 weeks， twice a day； 8 mg in 5-6 weeks， once a day； 8 mg in 7-8 weeks， once every 2 days； and 8 mg in 9-10 weeks， once every 3 days. The treatment course for both groups was 10 weeks. Clinical efficacy， and plasma histamine levels and total scores of signs and symptoms before and after treatment in 2 groups were observed， and recurrence and incidence of adverse reactions after 4 weeks of stopping drugs in 2 groups were followed-up. RESULTS： There were no significant difference in the total effective rate and incidence of adverse reactions between 2 groups（P＞0.05）. After treatment， the total scores of signs and symptoms in 2 groups were significantly lower than before， the difference was statistically significant（P＜0.01）， and there was no significant difference between 2 groups（P＞0.05）. The recurrence rate in group A was significantly lower than group B， the difference was statistically significant（P＜0.05）. CONCLUSIONS： Both efficacy and safety of desloratadine citrate disodium and acrivastine decremental therapy in the treatment of chronic urticaria are good， however， desloratadine citrate disodium is better than acrivastine in reducing recurrence rate. |
| 期刊： | 2015年第26卷第36期 |
| 作者： | 董东，何小亮，杨德勇，王晓霞 |
| AUTHORS： | DONG Dong，HE Xiao-liang，YANG De-yong，WANG Xiao-xia |
| 关键字： | 枸地氯雷他定；阿伐斯汀；慢性荨麻疹；递减疗法；疗效；安全性 |
| KEYWORDS： | Desloratadine citrate disodium； Acrivastine； Chronic urticaria； Decremental therapy；Efficacy； Safety |
| 阅读数： | 1401 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
